Leerink Partners Initiates Coverage on Maze Therapeutics (NASDAQ:MAZE)

Investment analysts at Leerink Partners began coverage on shares of Maze Therapeutics (NASDAQ:MAZE) in a note issued to investors on Tuesday,Benzinga reports. The brokerage set an “outperform” rating and a $28.00 price target on the stock. Leerink Partners’ price target would suggest a potential upside of 158.78% from the stock’s current price.

Maze Therapeutics Stock Performance

Shares of NASDAQ MAZE opened at $10.82 on Tuesday. Maze Therapeutics has a 12-month low of $10.66 and a 12-month high of $17.00.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.